OncRef

Clinical Trial: NCT04703686

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:The Lymphoma Academic Research Organisation
Information Provided By:The Lymphoma Academic Research Organisation
Last Update Posted:2026-03-16

Study Overview

Brief Summary

This study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy:

  • cohort 1: DLBCL patients
  • cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) or iNHL CAR T-cells Refractory/Relapse status will be determined by PET-CT central review allowing inclusion in this trial.

Patients enrolled will then receive a pre-phase of obinutuzumab followed by experimental treatment:11 cycle of glofitamab.

The primary objective of the study is to assess the anti-lymphoma activity of glofitamab, a bispecific CD3xCD20 monoclonal antibody in patients with relapse/refractory DLBCL (cohort 1) disease after anti-CD19 CAR T-cells therapy

Official Title

A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Conditions

Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Refractory Mantle Cell Lymphoma

Intervention / Treatment

  • Drug: Obinutuzumab
  • Drug: RO7082859

Other Study ID Numbers

  • BiCAR

Start Date (Actual)

2021-03-30

Primary Completion Date (Actual)

2023-01-10

Study Completion Date (Actual)

2025-05-21

Enrollment (Actual)

67

Study Type

Interventional

Phase

Phase 2